

PRIOR AUTHORIZATION POLICY

POLICY: Colony Stimulating Factors – Granix Prior Authorization Policy

- Granix® (tbo-filgrastim subcutaneous injection – Teva)

REVIEW DATE: 08/31/2022

OVERVIEW

Granix, a leukocyte growth factor, is indicated to reduce the duration of severe neutropenia in adults and pediatric patients 1 month of age and older with non-myeloid malignancies receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of febrile neutropenia.¹

Guidelines

The National Comprehensive Cancer Network (NCCN) addresses the use of Granix in guidelines.

- **Hematopoietic Cell Transplantation:** Guidelines (version 1.2022 – April 1, 2022) recommend filgrastim for hematopoietic cell mobilization for allogeneic or autologous donors as a single agent or in combination with other treatments.⁵ NCCN states Granix is an appropriate substitute for filgrastim.
- **Hematopoietic Growth Factors:** Guidelines (version 1.2022 – December 22, 2021) recommend Granix, along with other granulocyte colony stimulating factors (CSFs), for prophylactic use if the patient is receiving anti-cancer medications that are associated with a high (> 20%) incidence of severe neutropenia with fever.² Consider CSF therapy for patients with an intermediate (10% to 20%) probability of developing febrile neutropenia based on risk factors. The NCCN guidelines also recommend therapy with CSFs in other scenarios in those given myelosuppressive chemotherapy. Granix is also recommended for mobilization and following hematopoietic cell transplant.
- **Myelodysplastic Syndromes (MDS):** Guidelines (version 3.2022 – January 13, 2022) recommend Granix for use in certain patients with MDS (e.g., neutropenic patients with recurrent or resistant infections, combination use with epoetin alfa or Aranesp® [darbepoetin alfa injection] in patients with anemia).³

The American Society of Clinical Oncology clinical practice guidelines for the use of white blood cell growth factors (2015) recommends CSFs to reduce the risk of febrile neutropenia in patients receiving cancer chemotherapy.⁴ CSFs may be considered in patients receiving radiation therapy alone if prolonged delays secondary to neutropenia are expected. The guidelines state CSFs should be avoided in patients receiving concomitant chemotherapy and radiation therapy, particularly involving the mediastinum.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Granix. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Granix as well as the monitoring required for adverse events and long-term efficacy, approval requires Granix to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Granix is recommended in those who meet one of the following criteria:

FDA-Approved Indication

1. **Cancer in a Patient Receiving Myelosuppressive Chemotherapy.** Approve for 6 months if the patient meets the following (A and B):
 - A) Patient meets ONE of the following conditions (i, ii, iii, or iv):
 - i. Patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia (the risk is at least 20% based on the chemotherapy regimen); OR
 - ii. Patient meets both of the following (a and b):
 - a) Patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia, but the risk is less than 20% based on the chemotherapy regimen; AND
 - b) Patient has at least one risk factor for febrile neutropenia according to the prescriber; OR
Note: Examples of risk factors include age ≥ 65 years; prior chemotherapy or radiation therapy; persistent neutropenia; bone marrow involvement by tumor; recent surgery and/or open wounds; liver and/or renal dysfunction; poor performance status; or human immunodeficiency virus (HIV) infection.
 - iii. Patient meets both of the following (a and b):
 - a) Patient has had a neutropenic complication from prior chemotherapy and did not receive prophylaxis with a colony stimulating factor; AND
Note: Examples of colony stimulating factors include filgrastim products, pegfilgrastim products, and sargramostim products (e.g., Leukine).
 - b) A reduced dose or frequency of chemotherapy may compromise treatment outcome; OR
 - iv. Patient who has received chemotherapy has febrile neutropenia and has at least one risk factor for poor clinical outcomes or for developing infection-associated complications according to the prescriber; AND
Note: Examples of risk factors include sepsis syndrome; age > 65 years; severe neutropenia (absolute neutrophil count [ANC] < 100 cells/mm³); neutropenia expected to be > 10 days in duration; invasive fungal infection; or other clinically documented infections.
 - B) The medication is prescribed by or in consultation with an oncologist or hematologist.

Other Uses with Supportive Evidence

2. **Myelodysplastic Syndromes.** Approve for 3 months if prescribed by or in consultation with an oncologist or hematologist.
3. **Peripheral Blood Progenitor Cell Collection and Therapy.** Approve for 1 month if prescribed by or in consultation with an oncologist, a hematologist, or a physician who specializes in transplantation.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Granix is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.



EmblemHealth®

ConnectiCare

REFERENCES

1. Granix[®] subcutaneous injection [prescribing information]. North Wales, PA: Teva; April 2020.
2. The NCCN Hematopoietic Growth Factors Clinical Practice Guidelines in Oncology (version 1.2022 – December 22, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on August 16, 2022.
3. The NCCN Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology (version 3.2022 – January 13, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed: August 16, 2022.
4. Smith TJ, Bohlke K, Lyman GH, Carson KR, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2015;33(28):3199-3212.
5. The NCCN Hematopoietic Cell Transplantation Clinical Practice Guidelines in Oncology (version 1.2022 – April 1, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on August 16, 2022.